Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis.

Vascular cell

George EM, Liu H, Robinson GG, Mahdi F, Perkins E, Bidwell GL.
PMID: 25653833
Vasc Cell. 2015 Jan 24;7(1):1. doi: 10.1186/s13221-014-0026-3. eCollection 2015.

BACKGROUND: Therapeutic angiogenesis with vascular endothelial growth factor (VEGF), delivered either via recombinant protein infusion or via gene therapy, has shown promise in preclinical models of various diseases including myocardial infarction, renovascular disease, preeclampsia, and neurodegenerative disorders. However, dosing,...

Cite
George EM, Liu H, Robinson GG, et al. Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell. 2015;7(1):1doi: 10.1186/s13221-014-0026-3.
George, E. M., Liu, H., Robinson, G. G., Mahdi, F., Perkins, E., & Bidwell, G. L. (2015). Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vascular cell, 7(1), 1. https://doi.org/10.1186/s13221-014-0026-3
George, Eric M, et al. "Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis." Vascular cell vol. 7,1 (2015): 1. doi: https://doi.org/10.1186/s13221-014-0026-3
George EM, Liu H, Robinson GG, Mahdi F, Perkins E, Bidwell GL. Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis. Vasc Cell. 2015 Jan 24;7(1):1. doi: 10.1186/s13221-014-0026-3. eCollection 2015. PMID: 25653833; PMCID: PMC4316602.
Copy Download .nbib Format: NLM
Renal Revascularization Attenuates Myocardial Mitochondrial Damage and Improves Diastolic Function in Pigs with Metabolic Syndrome and Renovascular Hypertension.

Journal of cardiovascular translational research

Farahani RA, Yu S, Ferguson CM, Zhu XY, Tang H, Jordan KL, Saadiq IM, Herrmann SM, Chade AR, Lerman A, Lerman LO, Eirin A.
PMID: 34269985
J Cardiovasc Transl Res. 2021 Jul 16; doi: 10.1007/s12265-021-10155-3. Epub 2021 Jul 16.

Percutaneous transluminal renal angioplasty (PTRA) may improve cardiac function in renovascular hypertension (RVH), but its effect on the biological mechanisms implicated in cardiac damage remains unknown. We hypothesized that restoration of kidney function by PTRA ameliorates myocardial mitochondrial damage...

Cite
Farahani RA, Yu S, Ferguson CM, et al. Renal Revascularization Attenuates Myocardial Mitochondrial Damage and Improves Diastolic Function in Pigs with Metabolic Syndrome and Renovascular Hypertension. J Cardiovasc Transl Res. 2021;doi: 10.1007/s12265-021-10155-3.
Farahani, R. A., Yu, S., Ferguson, C. M., Zhu, X. Y., Tang, H., Jordan, K. L., Saadiq, I. M., Herrmann, S. M., Chade, A. R., Lerman, A., Lerman, L. O., & Eirin, A. (2021). Renal Revascularization Attenuates Myocardial Mitochondrial Damage and Improves Diastolic Function in Pigs with Metabolic Syndrome and Renovascular Hypertension. Journal of cardiovascular translational research, . https://doi.org/10.1007/s12265-021-10155-3
Farahani, Rahele A, et al. "Renal Revascularization Attenuates Myocardial Mitochondrial Damage and Improves Diastolic Function in Pigs with Metabolic Syndrome and Renovascular Hypertension." Journal of cardiovascular translational research vol. (2021). doi: https://doi.org/10.1007/s12265-021-10155-3
Farahani RA, Yu S, Ferguson CM, Zhu XY, Tang H, Jordan KL, Saadiq IM, Herrmann SM, Chade AR, Lerman A, Lerman LO, Eirin A. Renal Revascularization Attenuates Myocardial Mitochondrial Damage and Improves Diastolic Function in Pigs with Metabolic Syndrome and Renovascular Hypertension. J Cardiovasc Transl Res. 2021 Jul 16; doi: 10.1007/s12265-021-10155-3. Epub 2021 Jul 16. PMID: 34269985; PMCID: PMC8761225.
Copy Download .nbib Format: NLM
Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer.

Pharmaceutics

Mahdi F, Chade AR, Bidwell GL.
PMID: 31635263
Pharmaceutics. 2019 Oct 18;11(10). doi: 10.3390/pharmaceutics11100542.

Elastin-like polypeptides (ELP) are versatile protein biopolymers used in drug delivery due to their modular nature, allowing fusion of therapeutics and targeting agents. We previously developed an ELP fusion with vascular endothelial growth factor (VEGF) and demonstrated its therapeutic...

Cite
Mahdi F, Chade AR, Bidwell GL. Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. Pharmaceutics. 2019;11(10)doi: 10.3390/pharmaceutics11100542.
Mahdi, F., Chade, A. R., & Bidwell, G. L. (2019). Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. Pharmaceutics, 11(10), . https://doi.org/10.3390/pharmaceutics11100542
Mahdi, Fakhri, et al. "Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer." Pharmaceutics vol. 11,10 (2019). doi: https://doi.org/10.3390/pharmaceutics11100542
Mahdi F, Chade AR, Bidwell GL. Utilizing a Kidney-Targeting Peptide to Improve Renal Deposition of a Pro-Angiogenic Protein Biopolymer. Pharmaceutics. 2019 Oct 18;11(10). doi: 10.3390/pharmaceutics11100542. PMID: 31635263; PMCID: PMC6835230.
Copy Download .nbib Format: NLM
Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform.

Physiology (Bethesda, Md.)

Bidwell GL.
PMID: 34486397
Physiology (Bethesda). 2021 Nov 01;36(6):367-381. doi: 10.1152/physiol.00026.2021. Epub 2021 Sep 06.

Elastin-like polypeptides (ELPs) are bioengineered proteins that have a unique physical property, a thermally triggered inverse phase transition, that can be exploited for drug delivery. ELP-fusion proteins can be used as soluble biologics, thermally targeted drug carriers, self-assembling nanoparticles,...

Cite
Bidwell GL. Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. Physiology (Bethesda). 2021;36(6):367-381doi: 10.1152/physiol.00026.2021.
Bidwell, G. L. (2021). Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. Physiology (Bethesda, Md.), 36(6), 367-381. https://doi.org/10.1152/physiol.00026.2021
Bidwell, Gene L. "Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform." Physiology (Bethesda, Md.) vol. 36,6 (2021): 367-381. doi: https://doi.org/10.1152/physiol.00026.2021
Bidwell GL. Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform. Physiology (Bethesda). 2021 Nov 01;36(6):367-381. doi: 10.1152/physiol.00026.2021. Epub 2021 Sep 06. PMID: 34486397; PMCID: PMC8560375.
Copy Download .nbib Format: NLM
Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia.

Frontiers in pharmacology

Bidwell GL, George EM.
PMID: 25249978
Front Pharmacol. 2014 Sep 05;5:201. doi: 10.3389/fphar.2014.00201. eCollection 2014.

The last several decades have seen intensive research into the molecular mechanisms underlying the symptoms of preeclampsia. While the underlying cause of preeclampsia is believed to be defective placental development and resulting placental ischemia, it is only recently that...

Cite
Bidwell GL, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014;5:201doi: 10.3389/fphar.2014.00201.
Bidwell, G. L., & George, E. M. (2014). Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Frontiers in pharmacology, 5201. https://doi.org/10.3389/fphar.2014.00201
Bidwell, Gene L, and George, Eric M. "Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia." Frontiers in pharmacology vol. 5 (2014): 201. doi: https://doi.org/10.3389/fphar.2014.00201
Bidwell GL, George EM. Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia. Front Pharmacol. 2014 Sep 05;5:201. doi: 10.3389/fphar.2014.00201. eCollection 2014. PMID: 25249978; PMCID: PMC4155872.
Copy Download .nbib Format: NLM
VEGF: Potential therapy for renal regeneration.

F1000 medicine reports

Chade AR.
PMID: 22238513
F1000 Med Rep. 2012;4:1. doi: 10.3410/M4-1. Epub 2012 Jan 03.

Vascular endothelial growth factor (VEGF) plays a central role in angiogenesis. A number of studies have focused on its role in health and disease and discussed the possibility of VEGF as both a therapeutic tool and target based on...

Cite
Chade AR. VEGF: Potential therapy for renal regeneration. F1000 Med Rep. 2012;4:1doi: 10.3410/M4-1.
Chade, A. R. (2012). VEGF: Potential therapy for renal regeneration. F1000 medicine reports, 41. https://doi.org/10.3410/M4-1
Chade, Alejandro R. "VEGF: Potential therapy for renal regeneration." F1000 medicine reports vol. 4 (2012): 1. doi: https://doi.org/10.3410/M4-1
Chade AR. VEGF: Potential therapy for renal regeneration. F1000 Med Rep. 2012;4:1. doi: 10.3410/M4-1. Epub 2012 Jan 03. PMID: 22238513; PMCID: PMC3251310.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries